Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer

Table 1

Basic clinicopathological features of PCa patients in early BCR and long-term survival groups before and after PS matching in the discovery set.

Variables	Discovery set
	Before matching			After matching
	Long-term survival (%)	Early BCR (%)		Long-term survival (%)	Early BCR (%)
Age (mean, IQR)	60.6 (56.0-66.0)	62.6 (59.0-66.0)	0.153	62.43 (57.0-68.0)	62.43 (58.0-66.0)	1
Gleason score			<0.001			1
6	5 (4.9)	0 (0.0)		0 (0.0)	0 (0.0)
7	63 (61.2)	8 (25.8)		6 (26.1)	6 (26.1)
8	12 (12.6)	4 (12.9)		4 (17.4)	4 (17.4)
9-10	22 (21.4)	19 (61.3)		13 (56.5)	13 (56.5)
T stage			0.020			1
T2	40 (38.8)	3 (9.7)		3 (13.0)	3 (13.0)
T3	59 (57.3)	27 (87.1)		20 (87.0)	20 (87.0)
T4	4 (3.9)	1 (3.2)		0 (0.0)	0 (0.0)
N stage			0.008			1
N0	91 (88.3)	22 (71.0)		17 (73.9)	17 (73.9)
N1	12 (11.7)	9 (29.0)		6 (26.1)	6 (26.1)
Total	103 (100)	31 (100)		23 (100)	23 (100)